Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin's Lymphoma

被引:12
|
作者
Alfaifi, Abdullah [1 ,2 ]
Refai, Mohammed Y. [3 ]
Alsaadi, Mohammed [1 ,4 ]
Bahashwan, Salem [4 ,5 ,6 ]
Malhan, Hafiz [7 ]
Al-Kahiry, Waiel [7 ]
Dammag, Enas [7 ]
Ageel, Ageel [7 ]
Mahzary, Amjed [8 ]
Albiheyri, Raed [1 ]
Almehdar, Hussein [1 ]
Qadri, Ishtiaq [1 ]
机构
[1] King Abdulaziz Univ, Fac Sci, Dept Biol Sci, Jeddah 21589, Saudi Arabia
[2] Minist Hlth, Fayfa Gen Hosp, Jazan 83581, Saudi Arabia
[3] Univ Jeddah, Coll Sci, Dept Biochem, Jeddah 21493, Saudi Arabia
[4] King Abdulaziz Univ, King Fahad Med Res Ctr, Hematol Res Unit, Jeddah 21589, Saudi Arabia
[5] King Abdulaziz Univ, Fac Med, Dept Hematol, Jeddah 21589, Saudi Arabia
[6] King Abdulaziz Univ, King Abdulaziz Univ Hosp, Jeddah 21589, Saudi Arabia
[7] Minist Hlth, Prince Mohammed Bin Nasser Hosp, Jazan 82943, Saudi Arabia
[8] Minist Hlth, Eradah Hosp, Jazan 82943, Saudi Arabia
关键词
metabolomics; B-cell non-Hodgkin's lymphoma; biomarkers; metabolites; early diagnosis; therapeutic; GENOMIC URACIL; LARGE-SCALE; METABOLISM; SERUM; INHIBITION; MUTATIONS; EXPRESSION; LEUKEMIA; SURVIVAL; CHROMATOGRAPHY;
D O I
10.3390/diagnostics13050861
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A wide range of histological as well as clinical properties are exhibited by B-cell non-Hodgkin's lymphomas. These properties could make the diagnostics process complicated. The diagnosis of lymphomas at an initial stage is essential because early remedial actions taken against destructive subtypes are commonly deliberated as successful and restorative. Therefore, better protective action is needed to improve the condition of those patients who are extensively affected by cancer when diagnosed for the first time. The development of new and efficient methods for early detection of cancer has become crucial nowadays. Biomarkers are urgently needed for diagnosing B-cell non-Hodgkin's lymphoma and assessing the severity of the disease and its prognosis. New possibilities are now open for diagnosing cancer with the help of metabolomics. The study of all the metabolites synthesised in the human body is called "metabolomics." A patient's phenotype is directly linked with metabolomics, which can help in providing some clinically beneficial biomarkers and is applied in the diagnostics of B-cell non-Hodgkin's lymphoma. In cancer research, it can analyse the cancerous metabolome to identify the metabolic biomarkers. This review provides an understanding of B-cell non-Hodgkin's lymphoma metabolism and its applications in medical diagnostics. A description of the workflow based on metabolomics is also provided, along with the benefits and drawbacks of various techniques. The use of predictive metabolic biomarkers for the diagnosis and prognosis of B-cell non-Hodgkin's lymphoma is also explored. Thus, we can say that abnormalities related to metabolic processes can occur in a vast range of B-cell non-Hodgkin's lymphomas. The metabolic biomarkers could only be discovered and identified as innovative therapeutic objects if we explored and researched them. In the near future, the innovations involving metabolomics could prove fruitful for predicting outcomes and bringing out novel remedial approaches.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children
    Minard-Colin, Veronique
    Auperin, Anne
    Pillon, Marta
    Burke, G. A. Amos
    Barkauskas, Donald A.
    Wheatley, Keith
    Delgado, Rafael F.
    Alexander, Sarah
    Uyttebroeck, Anne
    Bollard, Catherine M.
    Zsiros, Jozsef
    Csoka, Monika
    Kazanowska, Bernarda
    Chiang, Alan K.
    Miles, Rodney R.
    Wotherspoon, Andrew
    Adamson, Peter C.
    Vassal, Gilles
    Patte, Catherine
    Gross, Thomas G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (23) : 2207 - 2219
  • [32] Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy
    Her, Jung Hyun
    Pretscher, Dominik
    Patra-Kneuer, Maria
    Schanzer, Juergen
    Cho, Sung Yoo
    Hwang, Yu Kyeong
    Hoeres, Timm
    Boxhammer, Rainer
    Heitmueller, Christina
    Wilhelm, Martin
    Steidl, Stefan
    Endell, Jan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (11) : 2829 - 2836
  • [33] Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trials to clinical practice
    Juweid, ME
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (11) : 1507 - 1529
  • [34] The role of aldehyde dehydrogenase 1A1 in B-cell non-Hodgkin's lymphoma
    Song, Ying-Hui
    Zhong, Mei-Zuo
    Chai, Qin
    Gong, Kui-Yu
    Tan, Xiao-Lang
    Hu, Jin-Yue
    Wang, Gui-Hua
    ONCOLOGY REPORTS, 2018, 39 (03) : 1261 - 1268
  • [35] Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia
    Chu, Yu-Waye
    Polson, Andrew
    FUTURE ONCOLOGY, 2013, 9 (03) : 355 - 368
  • [36] The unexpected evolution of a case of diffuse large B-cell non-Hodgkin lymphoma
    Gaman, Amelia
    Bold, Adriana
    Gaman, G.
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2011, 52 (02) : 719 - 722
  • [37] Identification of Highly Methylated Genes across Various Types of B-Cell Non-Hodgkin Lymphoma
    Bethge, Nicole
    Honne, Hilde
    Hilden, Vera
    Troen, Gunhild
    Eknaes, Mette
    Liestol, Knut
    Holte, Harald
    Delabie, Jan
    Smeland, Erlend B.
    Lind, Guro E.
    PLOS ONE, 2013, 8 (11):
  • [38] Lack of TERT Promoter Mutations in Human B-Cell Non-Hodgkin Lymphoma
    Lam, Gary
    Xian, Rena R.
    Li, Yingying
    Burns, Kathleen H.
    Beemon, Karen L.
    GENES, 2016, 7 (11):
  • [39] Emerging Role of Podocalyxin in the Progression of Mature B-Cell Non-Hodgkin Lymphoma
    Tamayo-Orbegozo, Estibaliz
    Amo, Laura
    Diez-Garcia, Javier
    Amutio, Elena
    Rinon, Marta
    Alonso, Marta
    Arana, Paula
    Maruri, Natalia
    Larrucea, Susana
    CANCERS, 2020, 12 (02)
  • [40] Overlapping B-Cell Non-Hodgkin Lymphoma with Myeloid Malignancies: A Case Series
    Youssef, Ayman
    Badreldein, Mohamed
    Elghandour, Ashraf
    Eshba, Sara
    Eshra, Reem
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S313 - S313